Showing 1561-1570 of 3020 results for "".
- Good Deal: DS Healthcare Acquires Radiancy, Neovahttps://practicaldermatology.com/news/good-deal-ds-healthcare-acquires-radiancy-neova/2458692/DS Healthcare Group, Inc. will acquire Radiancy, Inc., and Neova® from PhotoMedex, Inc. The board of directors of both companies have voted unanimously in favor o
- New AAD Acne Guidelines Call for Combination Therapyhttps://practicaldermatology.com/news/new-aad-acne-guidelines-call-for-combination-therapy/2458695/Combination therapy is the way forward for treating moderate-to-mild acne, according to new guidelines from The American Academy of Dermatology. For example, antibiotics should be used with topical acne therapy, and patients should continue using topical treatments to manage their c
- Weleda Partners with NonProfit Group Offering Free Makeovers for Seniorshttps://practicaldermatology.com/news/weleda-gives-back-with-complimentary-makeovers-for-seniors/2458706/Natural skin care company Weleda is partnering with GlamourGals, a nonprofit group that provides complimentary beauty makeovers to senior citizens. Weleda will provide more than 7,000 tubes of Skin Fo
- Bristol-Myers Squibb Foundation Awards 8 Grants to Make Skin and Lung Cancer Screening More Accessible in High-Risk U.S. Communitieshttps://practicaldermatology.com/news/bristol-myers-squibb-foundation-awards-8-grants-to-make-skin-and-lung-cancer-screening-more-accessible-in-high-risk-us-communities/2458721/Bristol-Myers Squibb Foundation awarded eight grants totaling nearly $11.5 million to help make skin and lung cancer screening programs, care and patient support more accessible to underserved populations. The grants we
- Rosacea, Glioma Linked: Are MMPs the Common Denominator?https://practicaldermatology.com/news/rosacea-glioma-linked-are-mmps-the-common-denominator/2458730/Rosacea may increase risk for glioma, according to a nationwide cohort study in Denmark. The findings, published online in JAMA Dermatology, suggest that an increased focus on neurologic sympt
- Surgical Specialties Corporation Acquires FSSB Chirurgische Nadein GMBHhttps://practicaldermatology.com/news/surgical-specialties-corporation-acquires-fssb-chirurgische-nadein-gmbh/2458735/Surgical Specialties Corporation has acquired all shares of FSSB Chirurgische Nadein GMBH (FSSB) and affiliated entities. Terms were not disclosed. The acquisition will be immediately accretive to both Surgical Specialties' sales and adjusted EBITDA. FSSB was founded in 1995 by c
- Galderma Laboratories, L.P. Appoints Miles Harrison as Leader of U.S. and Canadahttps://practicaldermatology.com/news/galderma-laboratories-lp-appoints-miles-harrison-as-leader-of-us-and-canada/2458762/Galderma promoted Miles Harrison to President and General Manager of Galderma Laboratories, L.P. leading the US and Canada teams. Miles Harrison joined Galderma US in 2014 as the Vice President
- Valeant Issues Updated Financial Guidancehttps://practicaldermatology.com/news/valeant-issues-updated-financial-guidance/2458779/Valeant Pharmaceuticals International, Inc. announced updated financial guidance for the fourth quarter and full year 2015 as well as new guidance for full year 2016. "We are very excited about the strong future given our broad portfolio of brands, our upcoming launch products and ou
- Oculus Innovative Sciences Receives FDA Clearance for Microcyn-Based SebDerm Gelhttps://practicaldermatology.com/news/oculus-innovative-sciences-receives-fda-clearance-for-microcyn-based-sebderm-gel/2458780/Oculus Innovative Sciences, Inc. received a new 510(k) clearance from the FDA for the company’s new Microcyn®-based SebDerm Gel. As a prescription product, SebDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrh
- FDA Grants ReCell Expedited Access Pathway Designation to Treat Burnshttps://practicaldermatology.com/news/fda-grants-recell-expedited-access-pathway-designation-to-treat-burns/2458782/The FDA has ruled that the ReCell® Autologous Cell Harvesting Device from Avita Medical Ltd. is eligible for earlier regulatory approval for burns treatment. The ruling came under new FDA guidelines called the Expedited Access Pathway (EAP), which are aimed at helping patients get mor